ClinicalTrials.gg
CompletedNCT04206618Updated Jan 12, 2021

Circulating Myokine Levels and Bone Metabolism

An observational study in Osteoporosis, Postmenopausal, sponsored by 424 General Military Hospital. Completed at 1 site in Greece. Open to female participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by 424 General Military Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
220
Ages
20 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Osteoporosis, Postmenopausal with a site in Greece — 2 open to participants now, 3 under way, none of them phase 3. Osteoporosis, Postmenopausal · Greece.

Started
2019
the only one that year
Observational
7 of 14
2 open now
Registered
9th of 14
by date
Lead sponsor
4 of 14
424 General Military Hospital

Among the 14 studies in Osteoporosis, Postmenopausal with a site in Greece, this one is the only one that started in 2019, is one of 7 observational ones, and was the 9th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

2 of the 14 studies in Osteoporosis, Postmenopausal with a site in Greece are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 20 Years to 85 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Osteoporosis, Postmenopausal with a site in Greece, or all of them as a file.
02

Study summary

Circulating levels of several myokines will be measured in serum samples obtained from women in various categories of bone density and according to the presence of fracture or not as well as before and after treatment with teriparatide and denosumab

Read the detailed description

Serum samples for the measurement of several myokines will be obtained from: 1) equal groups of premenopausal women with normal BMD, postmenopausal women with normal BMD, postmenopausal women with osteopenia, and postmenopausal women with osteoporosis; 2) women with hip fracture compared with controls (women subjected to surgery due to knee osteoathritis); 3) women with osteoporosis treated with teriparatide or denosumab for 12 months

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Substudy 1: equal groups (n=25) of premenopausal women with normal BMD, postmenopausal women with normal BMD, postmenopausal women with osteopenia, and postmenopausal women with osteoporosis Substudy 2: postmenopausal women with an incident hip fracture (n=40) compared with controls (postmenopausal women with knee osteoarhtritis) Substudy 3: postmenopausal women with osteoporosis will receive treatment with either teriparatide or denosumab for 12 months

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Substudy 1:

  • adult women

Substudy 2:

  • women with an incident hip fracture

Substudy 3:

  • postmenopausal women with osteoporosis

Exclusion criteria

Exclusion Criteria:

  • secondary osteoporosis
  • any disease that could affect muscle and/or bone metabolism
  • any medication that could affect muscle and/or bone metabolism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
220 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • premenopausal normal

    premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage

  • postmenopausal normal

    postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage

  • postmenopausal osteopenia

    postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage

  • postmenopausal osteoporosis

    postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage

  • hip fracture

    postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis

  • controls (knee osteoarthitis)

    postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls

  • teriparatide group

    postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months

    Drug: Teriparatide

  • denosumab group

    postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months

    Drug: Denosumab

Interventions

  • 1 subcutaneous injection daily for 12 months

    Also known as: rhPTH 1-34

  • 1 subcutaneous injection every 6 months for 12 months

    Also known as: RANKL inhibitor

06

What researchers measure

Primary outcomes

  1. follistatin

    circulating levels of myokine follistatin at baseline and their changes at 3 and 12 months with treatment

    Time frame: 0,3,12 months

Secondary outcomes

  1. activin-A

    circulating levels of myokine activin-A at baseline and their changes at 3 and 12 months with treatment

    Time frame: 0,3,12 months

  2. FSTL3

    circulating levels of myokine FSTL3 at baseline and their changes at 3 and 12 months with treatment

    Time frame: 0,3,12 months

  3. activin-B

    circulating levels of activin-B at baseline and their changes at 3 and 12 months with treatment

    Time frame: 0,3,12 months

  4. irisin

    circulating levels of myokine irisin at baseline and their changes at 3 and 12 months with treatment

    Time frame: 0,3,12 months

07

Study locations

1 site
  • 424 General Military Hospital
    Thessaloniki, Northern Greece 56429, Greece
08

References and documents

Publications

  • Bowser M, Herberg S, Arounleut P, Shi X, Fulzele S, Hill WD, Isales CM, Hamrick MW. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp Gerontol. 2013 Feb;48(2):290-7. doi: 10.1016/j.exger.2012.11.004. Epub 2012 Nov 21. PubMed 23178301 ↗
  • Lotinun S, Pearsall RS, Horne WC, Baron R. Activin receptor signaling: a potential therapeutic target for osteoporosis. Curr Mol Pharmacol. 2012 Jun;5(2):195-204. doi: 10.2174/1874467211205020195. PubMed 21787285 ↗
  • Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Savvides M, Papatheodorou A, Terpos E. Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. Osteoporos Int. 2013 Jul;24(7):2127-32. doi: 10.1007/s00198-012-2198-0. Epub 2012 Nov 3. PubMed 23124716 ↗
  • Lodberg A, Eijken M, van der Eerden BCJ, Okkels MW, Thomsen JS, Bruel A. A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia. Bone. 2018 May;110:326-334. doi: 10.1016/j.bone.2018.02.026. Epub 2018 Feb 28. PubMed 29499419 ↗
  • Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J, Bouxsein ML, Baron R. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010 Apr;46(4):1082-8. doi: 10.1016/j.bone.2010.01.370. Epub 2010 Jan 18. PubMed 20080223 ↗
  • Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009 Apr;24(4):744-52. doi: 10.1359/jbmr.081208. PubMed 19049340 ↗
  • Fahmy-Garcia S, Farrell E, Witte-Bouma J, Robbesom-van den Berge I, Suarez M, Mumcuoglu D, Walles H, Kluijtmans SGJM, van der Eerden BCJ, van Osch GJVM, van Leeuwen JPTM, van Driel M. Follistatin Effects in Migration, Vascularization, and Osteogenesis in vitro and Bone Repair in vivo. Front Bioeng Biotechnol. 2019 Mar 1;7:38. doi: 10.3389/fbioe.2019.00038. eCollection 2019. PubMed 30881954 ↗
  • Lodberg A, van der Eerden BCJ, Boers-Sijmons B, Thomsen JS, Bruel A, van Leeuwen JPTM, Eijken M. A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice. FASEB J. 2019 May;33(5):6001-6010. doi: 10.1096/fj.201801969RR. Epub 2019 Feb 13. PubMed 30759349 ↗

Individual participant data

Plan to share: Undecided — Data will become available after study completion

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Sep 2020, 15 months.

Of 23 observational studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2019
First posted
Dec 20, 2019
StartActual
Jun 1, 2019
Primary completionActual
Sep 30, 2020
CompletionActual
Nov 10, 2020
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04206618
Lead sponsor
424 General Military Hospital
Responsible party
Athanasios D. Anastasilakis (Principal Investigator, 424 General Military Hospital) — Principal investigator
First posted
Dec 20, 2019
Start date
Jun 1, 2019
Primary completion
Sep 30, 2020
Completion
Nov 10, 2020
Last update
Jan 12, 2021

Study contacts

Athanasios Anastasilakis, phD
principal investigator · 424 General Military Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion